Kairos Pharma made changes to a deal with Helena Global, including a new price and extended credit.

Nov 3, 2026, 11:55 AM ETDealRead the original at SEC EDGAR

Neutral

Kairos extended its credit-line option through December 31, 2028. Shares would sell for 97% of average share price using a 1-day window, and the filing reports no cash draw or new trial results, leaving the outlook unchanged.

KAPA · Kairos Pharma, LTD.

AI read · Neutral

The AI's read

This gives Kairos another way to seek cash. But using the line means selling shares below the average price, which can leave current owners with a smaller share of the company. The filing does not say Kairos drew money. It also announces a presentation of interim trial data, not new trial results, so it reports no new treatment update.

Get alerts for KAPA

Follow Kairos Pharma, LTD. (KAPA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KAPA

Free on the App Store and Google Play, or on the web.